Opinion

Video

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

Author(s):

Ronan J. Kelly, MD, MBA

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Download PDF
Related Videos
Elizabeth Buchbinder, MD
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Ritu Salani, MD
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT
December 13th 2024

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium
December 11th 2024

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium